High-dose carboplatin and etoposide for salvage chemotherapy of germ cell tumours

H. Lampe, D. P. Dearnaley, A. Price, J. Mehta, R. Powles, J. Nicholls, A. Horwich*

*Corresponding author for this work

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

We evaluated high-dose carboplatin and etoposide with autologous bone marrow stem cell support in the salvage treatment of patients with metastatic germ cell tumours who had failed previous chemotherapy. The treatment programme comprised initial conventional dose chemotherapy. 23 patients received a first cycle of high-dose treatment, and 12 who showed no evidence of progression had a second cycle 2-3 months later. 8 of the 23 patients treated with high-dose chemotherapy are alive in remission 4-29 months from the start of high-dose treatment. 3 of these 8 required further treatment for recurrence. In the initial part of the study, the dose of carboplatin was escalated in successive patients. Grade 3 4 treatment-related toxicity occurred in 4 of 18 patients (1 fatal) who received carboplatin doses to give a AUC (area under the serum concentration/time curve) of 30 mg.min/ml or less and 3 of 5 patients (2 fatal) who received higher doses. We, therefore, recommend 30 mg.min/ml for further evaluation in chemotherapy sensitive patients.

Original languageEnglish (US)
Pages (from-to)717-723
Number of pages7
JournalEuropean Journal of Cancer
Volume31
Issue number5
DOIs
StatePublished - 1995

Keywords

  • bone marrow transplantation
  • carboplatin
  • chemotherapy
  • etoposide
  • testicular neoplasm

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'High-dose carboplatin and etoposide for salvage chemotherapy of germ cell tumours'. Together they form a unique fingerprint.

  • Cite this

    Lampe, H., Dearnaley, D. P., Price, A., Mehta, J., Powles, R., Nicholls, J., & Horwich, A. (1995). High-dose carboplatin and etoposide for salvage chemotherapy of germ cell tumours. European Journal of Cancer, 31(5), 717-723. https://doi.org/10.1016/0959-8049(95)00018-E